Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

PROs Provide Insight On Atezolizumab/Bevacizumab Benefit in HCC

April 16th 2020

Peter R. Galle, MD, PhD, discusses the PROs analysis from the IMbrave150 trial in HCC and the importance of understanding patient experience during treatment.

Pemigatinib Pivotal Cholangiocarcinoma Data Published as FDA Weighs Approval

April 16th 2020

Data from the phase II FIGHT-202 study of pemigatinib in advanced or metastatic FGFR2-positive cholangiocarcinoma have been published as the FDA considers a new drug application for the treatment in this setting.

Dr. Shah on Optimal Sequencing in Gastroesophageal Cancer

April 15th 2020

Manish A. Shah, MD, discusses an optimal sequencing strategy in gastroesophageal cancer.

Multidisciplinary Care to Provide Best Possible Outcomes in HCC

April 15th 2020

Amit Singal, MD, MS, discussess optimal models for multidisciplinary care in hepatocellular carcinoma in light of the practice-changing IMbrave150 trial.

Dr. Janjigian on the JAVELIN Gastric 100 Study With Avelumab in Gastric/GEJ Cancer

April 14th 2020

Yelena Y. Janjigian, MD, discusses results from the phase III JAVELIN Gastric 100 study evaluating avelumab in gastric or gastroesophageal cancer.

Dr. O'Reilly on the Potential Role of Veliparib in Pancreatic Cancer

April 14th 2020

Eileen O'Reilly, MD, discusses the potential role of veliparib in pancreatic cancer.

Dr. Ilson on the Utility of Zolbetuximab in Claudin-Positive Gastric Cancers

April 14th 2020

David H. Ilson, MD, PhD, discusses the utility of zolbetuximab in claudin-positive gastric cancers.

Dr. Salem on the Role of Locoregional Therapy in HCC

April 14th 2020

Riad Salem, MD, discusses the role of locoregional therapy in hepatocellular carcinoma.

Dr. Katz on Neoadjuvant Chemotherapy in Pancreatic Cancer

April 14th 2020

Matthew H.G. Katz, MD, FACS, discusses the benefit of neoadjuvant chemotherapy in patients with pancreatic cancer.

Dr. Abou-Alfa on Sequencing Challenges in Metastatic HCC

April 11th 2020

Ghassan K. Abou-Alfa, MD, discusses sequencing challenges in metastatic hepatocellular carcinoma.

Dr. Chung on the Importance of Genomic Testing in Pancreatic Cancer

April 9th 2020

Vincent Chung, MD, discusses the importance of genomic testing in pancreatic cancer.

FDA Approves Encorafenib/Cetuximab Combo for BRAF+ mCRC

April 9th 2020

The FDA has approved the combination of encorafenib and cetuximab for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, following prior therapy.

Dr. Sapisochin on the Benefits of Living Donor Transplant in HCC

April 8th 2020

Gonzalo Sapisochin, MD, discusses the benefits of living donor liver transplantation in hepatocellular carcinoma.

Dr. O'Reilly on the Role of Germline Testing in Pancreatic Cancer

April 7th 2020

Eileen O'Reilly, MD, discusses germline testing in pancreatic cancer.

Talking HER2-Targeted Therapy With Dr. Marshall

April 7th 2020

We had the pleasure of speaking with John L. Marshall, MD, who discussed the evolving treatment landscape of HER2-targeted treatment strategies in colorectal cancer.

Talking HER2-Targeted Therapy With Dr. Chau

April 4th 2020

We had the pleasure of speaking with Ian Chau, MD, FRCP, who discussed the state of HER2-directed therapy in gastric/gastroesophageal cancer.

Talking HER2-Targeted Therapy With Dr. Ajani

April 4th 2020

We had the pleasure of speaking with Jaffer Ajani, MD, who discussed some of the investigational HER2-targeted treatment strategies with trastuzumab, antibody-drug conjugates, and bispecific antibodies that are under investigation in gastrointestinal malignancies.

Dr. Armaghany on Frontline Sorafenib Versus Lenvatinib in Unresectable HCC

April 4th 2020

Tannaz Armaghany, MD, discusses sorafenib versus lenvatinib as first-line therapy for patients with hepatocellular carcinoma.

Dr. Simeone on Selecting Patients With Pancreatic Cancer for Neoadjuvant Therapy

April 4th 2020

Diane M. Simeone, MD, explains which patients with pancreatic cancer should receive neoadjuvant therapy.

Talking HER2-Targeted Therapy With Dr. Corcoran

April 3rd 2020

We had the pleasure of speaking with Ryan Corcoran, MD, PhD, who discussed key takeaways regarding the use and investigation of HER2-targeted therapies in gastrointestinal malignancies.